Skip to main content
. Author manuscript; available in PMC: 2014 May 14.
Published in final edited form as: Mol Carcinog. 2011 Oct 17;51(12):952–962. doi: 10.1002/mc.20866

Figure 3.

Figure 3

Effect of apigenin and HDAC inhibitor TSA on the expression of class I HDACs in human prostate cancer cells. A, Inhibition of HDAC1 and HDAC3 protein expression at 20 μM and 40 μM doses of apigenin and 20 ng/ml HDAC inhibitor TSA for 24 h Panel 1, PC-3 cells and Panel 2, 22Rv1 cells. B, Inhibition of mRNA levels of HDAC1 and HDAC3 at 20 μM and 40 μM doses of apigenin and 20 ng/ml HDAC inhibitor TSA for 24 h Panel 1, PC-3 cells and Panel 2, 22Rv1 cells. Data represents the mean ± SD of three different assays. *P <0.05, and **P <0.001 versus control. The details are provided in ‘materials and methods’.